In general, suppression of certain transcription factors or proinflammatory cytokines such as NF-κB; e.g., with proteasome inhibitors in later-stage infections, and IFN I administration during early infection stages, could be beneficial in COVID-19 [107,108]. The gene discussed is NFKB1; the disease is infection.